Abstract:Abstract Programmed cell death-1 (PD-1) is a co-inhibitory protein that dampens TCR/CD28 signaling in part by recruiting the phosphatase SHP2 to the immunological synapse. Chronic antigenic restimulation of T cells can induce apoptosis or elicit PD-1-mediated exhaustion, rendering them hyporesponsive and ineffectual. While the checkpoint function of PD-1 has profound implications for cancer immunotherapy, the role of PD-1 in conventional effector T cell responses remains unclear. Restimulation-induced cell death (RICD) is a critical propriocidal apoptosis program triggered in activated T cells upon robust TCR re-engagement, constraining effector T cell expansion and longevity to prevent collateral tissue damage. We hypothesized that PD-1 attenuates RICD sensitivity in human effector T cells by modulating TCR signal strength. Here we show that transient upregulation of PD-1 helps to protect newly activated human CD4+ and CD8+ T cells from premature RICD during clonal expansion, with lesser effects noted in terminally differentiated T cells. Both antibody-mediated blockade of PD-1-PD-L1 and SHP2 inhibition increased RICD sensitivity to a similar extent. Conversely, concomitant addition of recombinant PD-L1 with TCR restimulation significantly reduced RICD in a dose-dependent manner, with more pronounced protection noted uopn CD28 coligation. Our ongoing work aims to define the role of recently discovered downstream PD-1 signaling nodes (e.g. PAG, VRK2) and specific pro/anti-apoptotic proteins in this process. These findings present significant implications for understanding how PD-1 blockade may influence apoptosis sensitivity in both normal and exhausted T cells to alter adaptive immune responses. Supported by grants from NIH (R35GM139619)

Identification of CD112R As a Novel Checkpoint for Human T Cells.

The CD112R/CD112 Axis: a Breakthrough in Cancer Immunotherapy

The ITPRIPL1- CD3ε Axis: a Novel Immune Checkpoint Controlling T Cells Activation

Cis Interactions Between CD2 and Its Ligands on T Cells Are Required for T Cell Activation

CD137, an attractive candidate for the immunotherapy of lung cancer.

CD137L Promotes Immune Surveillance in Melanoma Via HLTF Regulation

PD-1 protects expanding human T cells from premature restimulation-induced cell death.

Identification of A Biological Ligand for Human Plasmacytid Dendritic Cell Receptor Ilt7

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

P3.12-13 Expression of the Immune Checkpoint Axis-PVR/TIGIT in Small Cell Lung Cancer

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions

TIGIT axis: novel immune checkpoints in anti-leukemia immunity

Checkpoints under Traffic Control: from and to Organelles

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

The Er Membrane-Anchored Ubiquitin Ligase Hrd1 is A Positive Regulator of T-Cell Immunity

A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals

De novo identification of CD4 + T cell epitopes

RNA-Binding Protein PCBP1/hnRNP E1 is an Intracellular Checkpoint for Shaping Effector Versus Regulatory T Cells in Immunity and Cancer

Identification of RNF114 As a Novel Positive Regulatory Protein for T Cell Activation.